Perspective Therapeutics, Inc. CATX

Rank #2120 · NYSE · $0.1B market cap

Audited by WithumSmith+Brown, PC, no going-concern flag in the latest filing.

Score

33.1

P/E

-1.7

P/B

1.74

ROE

-105.5%

Op. Margin

–%

Debt Ratio

67%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Weak

P/E -1.7x, P/B 1.74x. Ranks in the top 62% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -105.5%. Ranks in the top 94% of the universe.

Safety ★★★★☆

Good

Debt ratio 67%. Ranks in the top 29% of the universe.

Growth –

No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2013	–	$-0.0B	$-0.0B	$0.0B	–	26
2014	–	$-0.0B	$-0.0B	$0.0B	–	29
2015	–	$-0.0B	$-0.0B	$0.0B	–	45
2016	–	$-0.0B	$-0.0B	$0.0B	–	41
2017	–	$-0.0B	$-0.0B	$0.0B	–	7
2018	$0.0B	$-0.0B	$-0.0B	$0.0B	-106.6	8
2019	$0.0B	$-0.0B	$-0.0B	$0.0B	-132.5	15
2020	$0.0B	$-0.0B	$-0.0B	$0.0B	-113.6	16
2021	$0.0B	$-0.0B	$-0.0B	$0.0B	-71.8	59
2022	$0.0B	$-0.0B	$-0.0B	$0.0B	-35.9	39
2023	$0.0B	$-0.0B	$-0.0B	$0.1B	–	5
2024	–	$-0.0B	$-0.0B	$0.1B	–	42
2025	–	$-0.1B	$-0.1B	$0.1B	–	67